Outlook Therapeutics Insider Buys $2.5M in OTLK at $0.99
A newly filed Form 4 shows Ghiath M. Sukhtian, an insider at Outlook Therapeutics, Inc. (OTLK), made a substantial open-market purchase of company stock. According to the filing, the transaction was dated August 12, 2026, and involved the purchase of 2,525,252 shares at a price of $0.99 per share, for a total outlay of $2,499,999.48. … Read more